Latest / The AI in Business Podcast
Determining Virtual Cell Impact for Drug Discovery - with Kristóf Szalay and Gerold Csendes of Turbine
Virtual cell models promise faster, cheaper early-stage drug discovery. However, the industry still lacks a shared way to judge which of these models can actually be trusted on a given problem.
In this episode, Kristóf Szalay, CTO and Co-Founder of Turbine, and Gerold Csendes, Scientist at Turbine, set out what virtual cell models can and can't do today, in conversation with host Marilie Fouché. They cover why benchmarking remains fragmented across the field, how pharma teams build confidence in a model before trusting it with real R&D decisions, and how compressing the feedback loop between…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.